Comparative Pharmacology
Head-to-head clinical analysis: LIORESAL versus ROBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIORESAL versus ROBAXIN.
LIORESAL vs ROBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 mL) as a single intravenous injection or infusion.
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant